Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients

Launched by ASTRAZENECA · Feb 5, 2009

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Provision of informed consent prior to any study specific procedures
• • A minimum of 6 months documented history of asthma according to the JGL2006/GINA2006 definition
• • FEV1\> 70% of predicted normal value pre-bronchodilator
• Exclusion Criteria:
• • Having a known or suspected allergy to study therapy (active drugs or additive)
• • Having a known clinical history of hypertension, relevant arrhythmias or other heart disease, eg, ischemic heart disease, cardiomyopathy, valvular heart disease, or heart failure
• • Having been treated with oral, parenteral or rectal glucocorticoids within 4 weeks, or with depot parenteral glucocorticoids within 3 months
• • Respiratory infection significantly affecting the asthma, as judged by the investigator within 4 weeks

Trial Officials